Keywords
COPD
hypertension
cardiovascular risk
How to Cite
Abstract
The combination of arterial hypertension, asthma and COPD has a significant prevalence in clinical practice. The presence of hypertension contributes to the growth of severity of asthma-COPD overlap (ACO), the worst prognosis and a high risk of cardiovascular complications. Coexistence of diseases changes the course of each of them, contributes to the early formation of complications and creates certain difficulties for therapy.
The aim of work was to investigate the factors of cardiovascular risk, as well as the arterial pressure indicators of patients with ACO.
Patients. 140 patients with ACO with an average forced expiratory volume for the first second (FEV1) (59.0 ± 1.4)% and the ratio of forced expiratory volume in the first second to the forced vital capacity of the lungs (FEV1 / FVC) (53.6 ± 0.8)%. Methods. All the patients underwent measurement of body weight and height, measurement of office systolic blood pressure (SBP), diastolic blood pressure (DBP), 24-hour ambulatory blood pressure monitoring (ABPM), biochemical blood test, coagulogram, assessment of total cardiovascular risk on a SCORE scale, the risk of cardiovascular complications on QRISK2 scale, the risk of developing diabetes mellitus (DM) on QDiabetes scale.
Results. Patients with ACO had some pathological changes in blood pressure. Also, these patients had a significant overload with arterial pressure. Also, in these patients, the diurnal index (DI) of SBP and DI DBP were significantly reduced relatively to normal values.
Patients with ACO predominantly belonged to the group of moderate risk of fatal cardiovascular events in 10 years (3.83%). The QRISK2 is quite significant, and is more than 15%. There is also a fairly significant risk of developing DM (more than 13%).
A higher concentration of inflammational markers was revealed in ACO patients with more severe bronchial obstruction (significant increase in C-reactive protein and fibrinogen with increased bronchial obstruction).
ACO patients from subgroups GOLD 1 and GOLD 2 predominantly belonged to the group of moderate risk, and patients from the GOLD 3.4 subgroup predominantly had a high risk of developing fatal cardiovascular events over the next 10 years (according to the SCORE scale). The QRISK2 scale risk was also moderate in the first two subgroups and high in patients with severe bronchial obstruction (GOLD 3,4).
Conclusions. In patients with a combination of asthma and COPD, significant cardiovascular comorbid pathology, a high prevalence of arterial hypertension, a high degree of overload with arterial pressure were found. Significant violations of the variability of blood pressure were also revealed. In this category of patients, a moderate risk of developing fatal cardiovascular events, as well as the development of diabetes within the next 10 years is also determined. Even more significant violations of blood pressure and high rates of cardiovascular risk were detected in patients with a combined pathology with a higher degree of bronchial obstruction.
References
Mostovyi Yu, Rasputina L. Khronichne obstruktyvne zakhvoriuvannia lehen ta sertsevo-sudynni zakhvoriuvannia: suchasnyi pohliad na problem. Zdorovia Ukraiiny. 2010;2:12-13.
Feshchenko Yu. Bronkhialna astma, khronichne obstruktyvne zakhvoriuvannia lehen: perspektyvna hlobalna stratehiia vedennia, novitni metody diahnostyky, suchasni pidkhody do terapii. Astma ta Alerhiia. 2015;4:38-42.
Yachnyk A, Svintsitskyi A, Shuper S. Khronichne obstruktyvne zakhvoriuvannia lehen ta ishemichna khvoroba sertsia: paraleli i perekhrestia komorbidnosti. Ukraiinskyi Pulmonolohichnyi Zhurnal. 2014;4:38-42.
Cazzola M, Calzetta L, Bettoncelli G et al. Cardiovascular disease in asthma and COPD: A population-based retrospective cross-sectional study. Respir Med. 2012; 106: 249-256. DOI: https://doi.org/10.1016/j.rmed.2011.07.021
Müllerova H, Agusti A, Erqou S, Mapel D.Cardiovascular comorbidity in COPD: systematic literature review. Chest. 2013; 144:1163-1178. DOI: https://doi.org/10.1378/chest.12-2847
Hillas G, Perlikos F, TsiligianniI, Tzanakis N. Managing comorbidities in COPD. Int J Chron Obstruct Pulmon Dis. 2015;10:95-109. DOI: https://doi.org/10.2147/COPD.S54473
Chandy D, Aronow W, Banach M. Current perspectives on treatment of hypertensive patients with chronic obstructive pulmonary disease. Integr Blood Press Control. 2013;6:101-109. DOI: https://doi.org/10.2147/IBPC.S33982
Dart R, Gollub S, Lazar J et al. Treatment of systemic hypertension in patients with pulmonary disease: COPD and asthma. Chest. 2003;123:222-243. DOI: https://doi.org/10.1378/chest.123.1.222 [PMid:12527626]
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017. Available from: http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/
Global Initiative for Asthma – GINA 2017. Available from: http://ginasthma.org/2017-gina-report-global-strategy-for-asthma-management-and-prevention/
Svishchenko EP, Bahrii AE, Yena LM et al. Arterialna hipertenziia. Onovlena ta adaptovana klinichna nastanova, zasnovana na dokazakh (2012 rik). Arterialna Hipertenziia. 2012;1(21):96-119.
2013 ESH/ESC Guidelines for the management of arterial hypertension. Blood Press. 2013;22(4):193-278. DOI: https://doi.org/10.3109/08037051.2013.812549
Franklin S, Wong N. Hypertension and cardiovascular disease: contributions of the Framingham Heart Study. Glob Heart. 2013;8:49-57. DOI: https://doi.org/10.1016/j.gheart.2012.12.004
Acelajado M, Oparil S. Hypertension and cardiovascular risk. 2013;6:182-194.
Cockroft D, Gailt M. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41. DOI: https://doi.org/10.1159/000180580
Sirenko Yu. Arterialna hipertenziia. Kyiv: Morion; c2002. 204p.
Pshenitsin A. Sutochnoe monitorirovanie arterialnogo davleniya: Posobie dlya vrachey. Medpraktika-M. 2007;2007:217.
Sirenko YuM. Hipertonichna khvoroba i arterialna hipertenziia. Donetsk: Zaslavskyi; c2011. 304p.
O'Brien E, Parati G, Stergiouc G et al. European society of hypertension position paper on ambulatory blood pressure monitoring. J Hypertens. 2013;9:1731-1768. DOI: https://doi.org/10.1097/HJH.0b013e328363e964
White WB. Blood pressure load and target organ effects in patients with essential hypertension. J Hypertens. 1991;9:39-41.
Cuspidi C, Giudici V, Negri F, Sala C. Nocturnal nondipping and left ventricular hypertrophy in hypertension: an updated review. Expert Rev Cardiovasc Ther. 2010;8:781-792. DOI: https://doi.org/10.1586/erc.10.29
An H, Park S, Yoo T et al. Non-dipper status and left ventricular hypertrophy as predictors of incident chronic kidney disease. J Korean Med Sci. 2011;26:1185-1190. DOI: https://doi.org/10.3346/jkms.2011.26.9.1185
Sherwood A, Bower J, Routledge F et al. Nighttime blood pressure dipping in postmenopausal women with coronary heart disease. Am J Hypertens. 2012;25:1077-1082. DOI: https://doi.org/10.1038/ajh.2012.95
Yan B, Sun L, Gao Y. Blood pressure reverse dipping may associate with stable coronary artery disease in patients with essential hypertension: a cross-sectional study. Sci Rep. 2016;6:25410. DOI: https://doi.org/10.1038/srep25410
Verdecchia P. Ambulatory pulse pressure: a potent predictor of total cardiovascular risk in hypertension. Hypertension. 1998;32:983-988. DOI: https://doi.org/10.1161/01.HYP.32.6.983 [PMid:9856961]
Gorbas IM. Shkala SCORE v Ukraiini: mozhlyvist vykorystannya. Mediks. Antyeidzhinh. 2010;2:22-26.
Hippisley-Cox J, Coupland C, Vinogradova Y et al. Performance of the QRISK cardiovascular risk prediction algorithm in an independent UK sample of patients from general practice: a validation study. Heart. 2008;94:34-39. DOI: https://doi.org/10.1136/hrt.2007.134890 [PMid:17916661]
Collins G, Altman D. External validation of QDSCORE (R) for predicting the 10-year risk of developing Type 2 diabetes. Diabet Med. 2011;28:59-607. DOI: https://doi.org/10.1111/j.1464-5491.2011.03237.x
Agustí A. Systemic effects of chronic obstructive pulmonary disease: what we know and what we don't know (but should). Proc Am Thorac Soc. 2007;4:522-525. DOI: https://doi.org/10.1513/pats.200701-004FM
Agusti A, EdwardsL, Rennard S et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One. 2012;7(5):e37483. DOI: https://doi.org/10.1371/journal.pone.0037483
Girdhar A, Kumar V, Singh A et al. Systemic inflammation and its response to treatment in patients with asthma. Respir Care. 2011;56:800-805. DOI: https://doi.org/10.4187/respcare.00601
Jousilahti P, Salomaa V, Hakala K et al. The association of sensitive systemic inflammation markers with bronchial asthma. Ann Allergy Asthma Immunol. 2002;89:381-385. DOI: https://doi.org/10.1016/S1081-1206(10)62039-X
Franklin S, Khan S, Wong N et al. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham heart study. Circulation. 1999;100:354-360. DOI: https://doi.org/10.1161/01.CIR.100.4.354 [PMid:10421594]
Khattar R, Swales J. Pulse pressure and prognosis. Heart. 2001;85:484-486. DOI: https://doi.org/10.1136/heart.85.5.484 [PMid:11302985 PMCid:PMC1729729]
Safar M, Blacher J, Jankowski P. Arterial stiffness, pulse pressure, and cardiovascular disease - is it possible to break the vicious circle? Atherosclerosis. 2011;218:263-271. DOI: https://doi.org/10.1016/j.atherosclerosis.2011.04.039
Kim S, Guevara J, Kim K et al. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum. 2009;61:885-892. DOI: https://doi.org/10.1002/art.24612
Grayson P, Kim S, LaValley M, Choi H. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res. 2011;63:102-110. DOI: https://doi.org/10.1002/acr.20344
Feig D, Kang D, Johnson R. Uric acid and cardiovascular risk. N Engl J Med. 2008;359:1811-1821. DOI: https://doi.org/10.1056/NEJMra0800885
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.